BERWYN, PA — Amring Pharmaceuticals Inc., a subsidiary of Nordic Group B.V., recently announced the appointment of Dr. Jai G. Parekh, MD, MBA, as Chief Commercial Officer, Eye Care U.S. This announcement comes as Nordic Pharma expands its pharmaceutical footprint in the U.S. following the acquisition of Visant Medical, Inc., a medical technology innovator in Dry Eye Disease (DED).
Key to the acquisition is the FDA-cleared hyaluronic acid derivative LACRIFILL®, a canalicular occlusive device designed to temporarily block tear drainage. Nordic Pharma’s expansion into the U.S. market and global plans for LACRIFILL® are set to be guided by Dr. Parekh’s strategic leadership and extensive experience in eye care.
Charlotte Phelps, CEO of Nordic Pharma, praised Dr. Parekh’s appointment, highlighting his patient-driven focus and deep understanding of the industry. “Dr. Parekh’s 25 years of eye care experience make him the perfect choice to guide our commercial entry into the U.S. market,” said Phelps.
Philip Gioia, President of the U.S. team launching LACRIFILL® under the Nordic Pharma brand, also expressed enthusiasm for Dr. Parekh’s new role. He pointed out Dr. Parekh’s innovative approach to eye care and his strong reputation in the industry. Moreover, he noted that the addition of Andy Corley of Yelroc Consulting as a commercial advisor to Nordic Pharma further strengthens their position as they prepare to launch LACRIFILL® later this year.
The appointment of Dr. Parekh and the formation of Nordic Pharma’s U.S. Medical Advisory Board signal strategic moves by Nordic Pharma to establish a strong foothold in the U.S. market. These developments could have significant implications for the treatment of dry eye disease, a condition that affects millions of people worldwide.
For industry insiders, these announcements underscore the growing importance and competitive landscape of eye care in the pharmaceutical sector. The acquisition of Visant Medical and the launch of LACRIFILL® present a significant opportunity for Nordic Pharma to leverage its innovative solutions in an expanding market.
Dr. Parekh expressed his anticipation for the role, stating, “I look forward to contributing to the growth and success of the organization by helping lead impactful commercial strategies.” He also noted the vast market opportunity for treating dry eye patients and expressed confidence that LACRIFILL® will be a significant part of their treatment options.
Dr. Parekh and Andy Corley are representing Nordic Pharma at the Hawaiian Eye and Retina 2024 meeting this week, where they are discussing LACRIFILL’s benefits with physicians and leaders in ophthalmology.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.